Which postoperative combined therapy results in the best prognosis: radiochemocytokine therapy or aggressive chemotherapy?
The recurrence of esophageal cancer involving regional nodes, even in patients who have undergone curative surgery, often takes place within three years after surgery. Thus, a new multidisciplinary treatment including cytokines or aggressive chemotherapy with active nutritional support to improve the prognosis in cancer of the thoracic esophagus has been adopted.